

Mean ± SEM		WT	IL4/IL13 <sup>-/-</sup>	STAT6 <sup>-/-</sup>	IL4Rα <sup>L/L</sup>	IL4Rα <sup>L/L</sup> LysM <sup>Cre</sup>
Food [g hr <sup>-1</sup> ]	30°C	0.14 ± 0.03	0.19 ± 0.02	0.16 ± 0.01	0.17 ± 0.02	0.13 ± 0.03
	22°C	0.12 ± 0.01	0.12 ± 0.01	0.14 ± 0.03	0.13 ± 0.01	0.14 ± 0.01
	4°C	0.39 ± 0.02	0.37 ± 0.10	0.31 ± 0.03	0.24 ± 0.04	0.21 ± 0.01
TG [mg dl <sup>-1</sup> ]	30°C	152.1 ± 11.91	153.5 ± 18.22	174.8 ± 10.23	152.1 ± 23.83	102.5 ± 22.78
	22°C	162.1 ± 14.38	164.6 ± 19.83	173.4 ± 23.63	148.9 ± 17.62	126.3 ± 19.05
	4°C	127.3 ± 10.53	103.9 ± 15.45	123.7 ± 10.62	126.7 ± 38.73	105.3 ± 45.15
Cholesterol [mg dl <sup>-1</sup> ]	30°C	91.74 ± 3.91	102.4 ± 5.37	105.9 ± 2.39	84.81 ± 16.76	91.29 ± 4.13
	22°C	115.9 ± 8.47	113.3 ± 8.00	95.65 ± 11.35	98.44 ± 5.05	89.4 ± 5.68
	4°C	115.5 ± 10.61	118.6 ± 6.19	113.3 ± 7.59	92.39 ± 4.77	84.12 ± 3.11
Body Weight [g]		21.44 ± 0.69	19.20 ± 0.42	20.26 ± 0.19	22.96 ± 0.40	21.77 ± 0.51
Weight Loss (%)		6.50 ± 2.19	3.41 ± 1.64 *	2.83 ± 1.79 **	7.38 ± 2.14	3.55 ± 1.21 **

Mean ± SEM		Liposome	Clodronate	C57BL/6J	C57BL/6J STAT6 <sup>-/-</sup>
Food [g hr <sup>-1</sup> ]	22°C	0.14 ± 0.03	0.14 ± 0.01	0.096 ± 0.01	0.13 ± 0.01
	4°C	0.23 ± 0.04	0.26 ± 0.02	0.21 ± 0.02	0.22 ± 0.02
TG [mg dl <sup>-1</sup> ]	22°C	133.3 ± 6.66	131.1 ± 17.66	166.1 ± 14.89	170.5 ± 12.79
	4°C	101.8 ± 2.53	123 ± 6.91	162.1 ± 11.01	157.9 ± 11.91
Cholesterol [mg dl <sup>-1</sup> ]	22°C	104.3 ± 4.17	131.2 ± 5.05	94.87 ± 4.88	92.75 ± 2.99
	4°C	111.3 ± 4.86	149.3 ± 7.41	86.21 ± 20.95	94.3 ± 5.16
Weight Loss (%)		7.84 ± 1.26 **	3.37 ± 2.61	7.30 ± 1.31 **	3.88 ± 1.16

**Supplementary Table 1. Metabolic characteristics of mice exposed to a cold challenge.**

\*P < 0.05, \*\*P < 0.01.


BAT [ng µg protein <sup>-1</sup> ]		IL4Rα <sup>L/L</sup>	IL4Rα <sup>L/L</sup> LysM <sup>Cre</sup>	Empty Liposome	Clodronate Liposome	C57BL/6J	C57BL/6J STAT6 <sup>-/-</sup>
Noradrenaline	22°C	9.88 ± 3.31	7.35 ± 3.35	7.58 ± 1.63	8.51 ± 2.39	7.25 ± 1.68	7.97 ± 2.19
	4°C	6.22 ± 1.91	1.64 ± 0.32 *	8.49 ± 1.86	3.16 ± 0.83 *	9.06 ± 1.25	1.29 ± 0.49 **
Adrenaline	22°C	7.47 ± 1.73	7.09 ± 1.49	4.08 ± 1.56	5.56 ± 1.44	8.85 ± 2.94	3.75 ± 1.42
	4°C	8.26 ± 0.65	4.08 ± 1.29 *	8.30 ± 1.89	1.34 ± 0.14 *	9.64 ± 2.76	1.34 ± 0.20 *
Dopamine	22°C	7.13 ± 1.60	7.93 ± 1.65	8.28 ± 1.63	7.40 ± 1.03	8.45 ± 1.31	7.32 ± 1.33
	4°C	6.51 ± 1.06	2.60 ± 0.94 *	6.26 ± 0.54	2.75 ± 0.52 **	8.77 ± 1.41	1.06 ± 0.32 **
WAT [pg µg protein <sup>-1</sup> ]		IL4Rα <sup>L/L</sup>	IL4Rα <sup>L/L</sup> LysM <sup>Cre</sup>	Empty Liposome	Clodronate Liposome	C57BL/6J	C57BL/6J STAT6 <sup>-/-</sup>
Noradrenaline	22°C	28.53 ± 6.82	20.87 ± 5.34	40.81 ± 6.80	43.04 ± 10.33	40.65 ± 8.41	42.03 ± 12.29
	4°C	18.17 ± 2.57	6.25 ± 1.04 **	42.32 ± 7.77	20.00 ± 5.25 *	34.52 ± 5.27	19.33 ± 2.34 *
Adrenaline	22°C	38.77 ± 9.09	37.85 ± 7.83	26.73 ± 2.91	24.29 ± 3.98	25.79 ± 2.97	27.76 ± 3.27
	4°C	32.98 ± 3.47	22.58 ± 2.09 *	25.71 ± 2.47	13.87 ± 2.41 *	28.64 ± 2.94	9.94 ± 1.61 **
Dopamine	22°C	15.86 ± 6.80	20.12 ± 6.26	28.62 ± 8.72	13.8 ± 5.30	22.72 ± 6.38	9.64 ± 3.11
	4°C	18.33 ± 3.22	3.72 ± 2.11**	26.92 ± 6.65	3.63 ± 0.34 *	23.62 ± 7.31	3.20 ± 0.99*

Supplementary Table 2. Catecholamine content of BAT and WAT in various strains of mice at 22 °C and 4 °C.


\*P < 0.05, \*\*P < 0.01.

Serum [ng ml <sup>-1</sup> ]		WT	IL4/IL13 <sup>-/-</sup>	STAT6 <sup>-/-</sup>	IL4R <sup>L/L</sup>	IL4R <sup>L/L</sup> LysM <sup>Cre</sup>
Noradrenaline	22°C	14.38 ± 0.89	13.07 ± 0.74	14.81 ± 2.37	15.92 ± 1.73	16.21 ± 3.51
	4°C	13.00 ± 0.46	12.34 ± 0.81	12.85 ± 2.50	14.51 ± 1.78	16.38 ± 4.16
Adrenaline	22°C	22.23 ± 7.95	19.72 ± 4.7	27.99 ± 9.91	27.4 ± 3.81	24.69 ± 3
	4°C	22.39 ± 6.39	24.9 ± 4.53	29.15 ± 7.24	29.96 ± 3.96	26.99 ± 3.01
Dopamine	22°C	19.43 ± 1.28	17.20 ± 4.51	16.79 ± 3.11	13.71 ± 2.60	17.14 ± 3.42
	4°C	14.98 ± 3.56	16.92 ± 1.42	13.21 ± 0.54	16.23 ± 6.91	20.43 ± 2.64
Liver [pg µg protein <sup>-1</sup> ]		WT	IL4/IL13 <sup>-/-</sup>	STAT6 <sup>-/-</sup>	IL4R <sup>L/L</sup>	IL4R <sup>L/L</sup> LysM <sup>Cre</sup>
Noradrenaline	22°C	13.66 ± 4.30	13.49 ± 6.08	13.06 ± 4.92	12.8 ± 4.65	12.53 ± 4.89
	4°C	18.7 ± 8.49	19.3 ± 10.91	18.57 ± 9.52	18.13 ± 9.49	17.51 ± 8.67
Adrenaline	22°C	21.69 ± 8.28	19.86 ± 6.76	20.19 ± 7.22	13.73 ± 5.59	32.73 ± 18.51
	4°C	33.01 ± 17.85	17.33 ± 5.97	28.45 ± 12.43	27.71 ± 5.77	28.98 ± 13.46
Dopamine	22°C	18.24 ± 8.40	23.6 ± 15.32	24.2 ± 15.18	18.31 ± 5.72	18.7 ± 5.80
	4°C	18.22 ± 6.93	22.18 ± 8.92	19.33 ± 4.45	14.51 ± 1.72	14.61 ± 2.68
Quadriceps [pg µg protein <sup>-1</sup> ]		WT	IL4/IL13 <sup>-/-</sup>	STAT6 <sup>-/-</sup>	IL4R <sup>L/L</sup>	IL4R <sup>L/L</sup> LysM <sup>Cre</sup>
Noradrenaline	22°C	0.37 ± 0.33	0.66 ± 0.65	0.79 ± 0.47	2.87 ± 0.80	1.80 ± 0.94
	4°C	0.43 ± 0.08	0.51 ± 0.29	0.64 ± 0.41	1.27 ± 0.82	1.13 ± 0.61
Adrenaline	22°C	2.21 ± 0.91	2.65 ± 0.80	2.73 ± 1.06	0.74 ± 0.55	0.88 ± 0.89
	4°C	0.92 ± 0.25	0.64 ± 0.16	1.03 ± 0.55	0.24 ± 0.11	0.62 ± 0.41
Dopamine	22°C	0.37 ± 0.33	0.66 ± 0.65	0.79 ± 0.47	0.75 ± 0.55	0.89 ± 0.89
	4°C	0.44 ± 0.07	0.50 ± 0.28	0.21 ± 0.11	0.24 ± 0.11	0.62 ± 0.42
Adrenal Gland [pg µg protein <sup>-1</sup> ]		WT	IL4/IL13 <sup>-/-</sup>	STAT6 <sup>-/-</sup>	IL4R <sup>L/L</sup>	IL4R <sup>L/L</sup> LysM <sup>Cre</sup>
Noradrenaline	22°C	50.84 ± 27.14	44.39 ± 3.95	33.82 ± 12.26	50.20 ± 25.95	35.87 ± 11.67
	4°C	45.17 ± 8.32	39.52 ± 4.89	37.44 ± 4.76	43.27 ± 7.63	39.76 ± 5.00
Adrenaline	22°C	20.82 ± 7.26	22.14 ± 4.66	19.9 ± 3.77	26.62 ± 11.43	22.95 ± 5.51
	4°C	22.12 ± 3.51	17.23 ± 2.53	19.25 ± 2.67	18.04 ± 2.75	18.12 ± 2.45
Dopamine	22°C	20.4 ± 5.85	18.45 ± 4.81	21.56 ± 1.34	23.95 ± 8.44	26.14 ± 3.83
	4°C	17.16 ± 1.34	13.99 ± 3.06	19.06 ± 2.08	25.14 ± 2.65	19.19 ± 3.81


Supplementary Table 3. Catecholamine content of tissues in various strains of mice at 22 °C and 4 °C.




**Supplementary Figure 1. Expression of alternative activation markers in adipose tissue macrophages.** **a, b,** Representative FACS plots of CD206 in BAT (a) and WAT (b) macrophages of WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 30 °C, 22 °C or 4 °C. **c, d,** Representative FACS plots of CD301 in BAT (c) and WAT (d) macrophages of WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 30 °C, 22 °C or 4 °C. **e, f,** Representative FACS plots of Arg1 in BAT (e) and WAT (f) macrophages of WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 30 °C, 22 °C or 4 °C.




**Supplementary Figure 2. Expression of inflammatory genes representative of classical macrophage activation in adipose tissue.** **a, b** BAT (a) and WAT (b) from WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 30 °C, 22 °C or 4 °C were analyzed by real-time PCR for expression of *Il1*, *Il6*, and *Tnfa* (n=4 per temperature). **c, d** BAT (c) and WAT (d) from IL4Rα<sup>L/L</sup> and IL4Rα<sup>L/L</sup>LysM<sup>Cre</sup> mice housed at 30 °C, 22 °C, and 4 °C were analyzed by real-time PCR for expression of *Il1*, *Il6*, and *Tnfa* (n=4 per temperature).



**Supplementary Figure 3. Macrophages are required for adaptation to cold temperatures.** **a**, BAT macrophage content in mice treated with empty (Veh) or clodronate-containing (Clod) liposomes (n=13-15 per treatment). **b**, Real-time PCR analysis of alternative activation markers in BAT of mice treated with Veh or Clod and then housed at 22 °C and 4 °C (n=5 per treatment and temperature). **c**, Core body temperature of mice treated with Veh or Clod after exposure to 4 °C (n=7-8 per treatment). **d, e**, Real-time PCR analysis of *Pparg1a* (d), *Ucp1*, and *Acs11*(e) in BAT of mice treated with Veh or Clod and housed at 22 °C or 4 °C (n=4-5 per treatment and temperature). \*\*P < 0.01, \*\*\*P < 0.001 compared to Veh. ΦP < 0.05, ΦΦP < 0.01 compared to Veh at 4 °C.




**Supplementary Figure 4. Depletion of macrophages and monocytes by clodronate-containing liposomes.** **a**, Representative FACS plots (*left*) and frequencies (*right*) of Ly6G<sup>+</sup> neutrophils and F4/80<sup>+</sup> macrophages in total splenocytes from mice treated with empty (Veh) or clodronate-containing (Clod) liposomes (n=2-3 per treatment). **b**, Representative FACS plots (*left*) and frequencies (*right*) of Ly6G<sup>+</sup> neutrophils and CD115<sup>+</sup> monocytes in total white blood cells from mice treated with Veh or Clod (n=2-3 per treatment).




**Supplementary Figure 5. a**, Immunoblot analysis of muscle cpt1 (Cpt1b) and cytochrome c oxidase (Cox1) in soleus muscles of WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 22 °C or 4 °C. **b**, Expression of lipogenic genes in liver of WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 30 °C, 22 °C or 4 °C (n=3 per genotype and temperature). **c, d**, Core body temperature of C57BL/6J WT and STAT6<sup>-/-</sup> mice housed at 4 °C for 6 hours (n=5 per genotype and temperature). **d**, Real-time PCR of *Acox1*, *Pparg1a*, and *Ucp1* mRNA levels in BAT of C57BL/6J WT and STAT6<sup>-/-</sup> mice housed at 22 °C and 4 °C (n=5 per genotype and temperature). \*\*P < 0.01, \*\*\*P < 0.001 comparison between WT and STAT6<sup>-/-</sup> at the same temperature.







**Supplementary Figure 6. Alternative activation induces expression of catecholamine synthesizing enzymes in macrophages.** **a-c**, Representative FACS plots demonstrating intracellular staining for tyrosine hydroxylase (Th), dopa decarboxylase (Ddc), and dopamine  $\beta$ -hydroxylase (Dbh) in wild type peritoneal macrophages treated with vehicle (Veh) or IL4 (10 ngml<sup>-1</sup>). Background staining was quantified using an appropriate isotype (Iso) control antibody. **d-f**, Th (d), Ddc (e), and Dbh (f) expression in wild type peritoneal macrophages stimulated with vehicle (Veh) or IL4 (10 ngml<sup>-1</sup>) for 24 hours (n=5 per condition). **g**, Representative FACS plots of tyrosine hydroxylase expression in WT and STAT6<sup>-/-</sup> peritoneal macrophages treated with IL4 (10 ngml<sup>-1</sup>). \*P<0.05, \*\*P < 0.01 compared to Veh.




**Supplementary Figure 7. Macrophage conditioned medium regulates lipolysis.** **a**, Adrenaline secretion by WT and STAT6<sup>-/-</sup> bone marrow-derived macrophages (BMDMs) stimulated with IL4 or LPS (n=5 per genotype and condition). **b**, Noradrenaline production by IL4-treated BMDMs in the presence or absence of  $\alpha$ -methyl-p-tyrosine (AMPT 2 mM, Sigma). **c**, Glycerol release by 3T3-L1 adipocytes after treatment with PIA, CL, IL4 or macrophage conditioned medium ( $\pm$  IL4 and AMPT) for 6 hours, n=4-6 per genotype and condition. \*\*\*P < 0.001 compared to WT with Veh.  $\Phi\Phi\Phi$  P < 0.001 compared to WT with IL4.




**Supplementary Figure 8. Flow cytometric gating strategy for tyrosine hydroxylase expression in adipose tissue macrophages. a, b,** Stromal vascular fractions were isolated from BAT (a) and WAT (b), and gated for side- and forward-scatter (SSC/FSC), doublets, and live cells prior to the analysis of the CD45<sup>+</sup>F4/80<sup>+</sup> macrophages. Tyrosine hydroxylase (Th) co-localizes with CD301 in BAT and WAT macrophages.




**Supplementary Figure 9. Tyrosine hydroxylase expression and catecholamine production by alternatively activated adipose tissue macrophages.** **a, c**, Tyrosine hydroxylase expression in BAT (a) and WAT (c) macrophages of IL4R $\alpha^{L/L}$  and IL4R $\alpha^{L/L}$ LysM<sup>Cre</sup> mice housed at 22 °C or 4 °C (n=4-5 per genotype and temperature). **b, d**, Noradrenaline content of BAT (b) and WAT (d) of IL4R $\alpha^{L/L}$  and IL4R $\alpha^{L/L}$ LysM<sup>Cre</sup> mice at various temperatures (n=4-5 per genotype and temperature). \*\*P < 0.01 comparison of values at 22°C and 4 °C in IL4R $\alpha^{L/L}$  mice.  $\Phi$ P < 0.05,  $\Phi\Phi$  < 0.01,  $\Phi\Phi\Phi$  < 0.001 comparison between IL4R $\alpha^{L/L}$  and IL4R $\alpha^{L/L}$ LysM<sup>Cre</sup> mice at the same temperature.




**Supplementary Figure 10. Human monocytes and macrophages produce catecholamines.** **a, e**, Expression of tyrosine hydroxylase and CD206 in primary monocytes (**a**) and human macrophage cell line U937 (**e**) treated with vehicle (Veh), IL4 (10 ngml<sup>-1</sup>), or lipopolysaccharide (LPS, 10 ngml<sup>-1</sup>), n=4-5 per condition. **b, f**, Catecholamine secretion by primary monocytes (**b**) and human macrophage cell line U937 (**f**) stimulated with IL4 or LPS, ( $\pm$  AMPT), n=4 per condition. **c, g**, Immunoblot analysis for phosphorylated-HSL and total HSL, phosphorylated-perilipin and total perilipin in 3T3-L1 adipocytes treated with PIA (1 mM), CL-316243 (1 mM), IL4 (10 ngml<sup>-1</sup>), primary monocyte (**c**) or U937 cell (**g**) conditioned medium ( $\pm$  IL4 and AMPT) for 15 min. PIA (N6-phenylisopropyl adenosine), AMPT (a-methyl-p-tyrosine). **d, h**, Glycerol release by 3T3-L1 adipocytes after 6h treatment with PIA, CL, IL4, primary monocyte (**d**) or U937 cell (**h**) conditioned medium (n=5 per condition). \*P < 0.05, \*\*P < 0.01 compared to Veh.



**Supplementary Figure 11. Characteristics of IL4/IL13<sup>-/-</sup> mice treated with  $\beta$ 3-adrenergic agonist CL-316243.** **a**, Core body temperature of WT, IL4/IL13<sup>-/-</sup> and IL4/IL13<sup>-/-</sup> mice treated with CL-316243 (n=5 per genotype and treatment). **b**, Real-time PCR analysis of thermogenic genes in BAT of WT, IL4/IL13<sup>-/-</sup> and IL4/IL13<sup>-/-</sup> mice treated with CL-316243 (n=4-5 per genotype and treatment). **c**, Cold (4 °C) induced weight loss in WT, IL4/IL13<sup>-/-</sup> and IL4/IL13<sup>-/-</sup> mice treated with CL-316243 (n=4-5 per genotype and treatment). **d-e**, Representative histology of BAT from WT, IL4/IL13<sup>-/-</sup> and IL4/IL13<sup>-/-</sup> mice treated with CL-316243 after exposure to 4 °C; gross (d) and haematoxylin and eosin stained sections (e). **f**, Serum free fatty acid (FFA) levels in WT, IL4/IL13<sup>-/-</sup>, and IL4/IL13<sup>-/-</sup> mice treated with CL-316243 housed at 22 °C or 4 °C (n=4-5 per condition and genotype). **g**, Real-time PCR of lipogenic genes (*Lpl*, *Dgat1*, *Hmgcs1*) in BAT of WT, IL4/IL13<sup>-/-</sup>, and IL4/IL13<sup>-/-</sup> mice treated with CL-316243 housed at 22 °C or 4 °C (n=4-5 per genotype and temperature). \*P < 0.05, \*\*P < 0.01, \*\*\* P < 0.001 compared to WT.




**Supplementary Figure 12. Cold challenge induces lipogenic gene expression in brown adipose tissue.** **a**, Real-time PCR of lipogenic genes (*Lpl*, *Dgat1*, *Hmgcs1*) in BAT of WT, IL4/IL13<sup>-/-</sup>, and STAT6<sup>-/-</sup> mice housed at 22 °C or 4 °C (n=4-5 per genotype and temperature). **b**, Real-time PCR of lipogenic genes (*Dgat1*, *Hmgcs1*) in BAT of IL4R $\alpha$ <sup>L/L</sup> and IL4R $\alpha$ <sup>L/L</sup>LysM<sup>Cre</sup> mice housed at 22 °C or 4 °C (n=4-5 per genotype and temperature).  $\Phi$ P < 0.05,  $\Phi\Phi$ P < 0.01,  $\Phi\Phi\Phi$ P < 0.001 compared to WT or IL4R $\alpha$ <sup>L/L</sup> at 4 °C.




**Supplementary Figure 13. Effects of IL4 in wild type mice housed at various temperatures.** **a, b**, Expression of alternative activation marker CD301 (a) and tyrosine hydroxylase (b) in adipose tissue macrophages of WT mice injected with vehicle (Veh) or IL4 at 30 °C, 22 °C or 4°C (n=4-5 per condition). **c**, Real-time RT-PCR analysis of thermogenic genes (*Acox1*, *Acs1*, *Ppargc1a*, and *Ucp1*) in BAT of WT mice treated with Veh or IL4 for 6h at various temperatures (n=4-5 per condition). **d**, Serum free fatty acid (FFA) levels of WT mice treated with Veh or IL4 for 6h at 30°C, 22°C, and 4°C (n=4-5 per condition). **e**, Noradrenaline content of serum and various tissues 30 minutes after injection of IL4. \*P < 0.05, \*\*P < 0.01, \*\*\* P < 0.001 compared to Veh.





**Supplementary Figure 14. Expression of CD301 and tyrosine hydroxylase in wild type mouse tissues at various temperatures.** **a, c, e,** Expression of CD301 was quantified by flow cytometry in wild type mice 6 hours after administration of vehicle (Veh) or IL4 at 30°C (**a**), 22°C (**c**), and 4°C (**e**) (n=4-5 per condition). **b, d, f,** Tyrosine hydroxylase expression was quantified in mouse tissue macrophages by flow cytometry 6 hours after injection of vehicle (Veh) or IL4 at 30°C (**d**), 22°C (**e**), and 4°C (**f**) (n=4-5 per condition). Bone marrow (BM). \*P < 0.05, \*\*P < 0.01, \*\*\* P < 0.001 compared to Veh.



**Supplementary Figure 15. Effects of IL4 in IL4R $\alpha^{L/L}$  and IL4R $\alpha^{L/L}$ LysM $^{Cre}$  mice.** **a, b**, Expression of CD301 (a) and tyrosine hydroxylase (b) in tissue macrophages of IL4R $\alpha^{L/L}$  and IL4R $\alpha^{L/L}$ LysM $^{Cre}$  mice treated with vehicle (Veh) or IL4 at 22°C (n=4-5 per genotype and condition). **c, d**, Locomotor activity of IL4R $\alpha^{L/L}$  and IL4R $\alpha^{L/L}$ LysM $^{Cre}$  mice (c), and liposome (Lipo) or clodronate-containing liposome (Clod) treated mice (d) after IL4 injection (n=7-8 per genotype and condition). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 compared to IL4R $\alpha^{L/L}$  with Veh.  $\Phi$ P < 0.05,  $\Phi\Phi$ P < 0.01,  $\Phi\Phi\Phi$ P < 0.001 compared to IL4R $\alpha^{L/L}$  with IL4.